These families help researchers find Alzheimer's treatments. Their network is at risk
The Alzheimer's Research Network Is Shrinking. 50 Million People Still Have Dementia.
What Happened
A network of families who volunteer their medical data and participation for Alzheimer's research is reportedly under threat — likely due to funding cuts or institutional instability. These families, many of whom carry genetic risk factors for early-onset Alzheimer's, have been critical to identifying treatment candidates. Without them, clinical trials and longitudinal studies lose their foundation.
Historical Context
Alzheimer's research has been underfunded relative to disease burden for decades. The disease affects roughly 50 million people worldwide and is the 7th leading cause of death in the U.S. Research networks like DIAN (Dominantly Inherited Alzheimer Network), founded in 2008, took years to build and have directly contributed to trials of drugs like lecanemab, approved by the FDA in 2023 — the first Alzheimer's drug to demonstrably slow cognitive decline. Patient registries are notoriously fragile: the Framingham Heart Study, which began in 1948, has faced repeated funding crises yet survived because of its irreplaceable longitudinal value. Research setbacks are real, but the science does not vanish — it pauses.
What's In Your Control
Whether you or a family member enroll in Alzheimer's research registries (nia.nih.gov lists open studies). Whether you contact your congressional representative if you believe NIH or NIA funding cuts are behind this. Whether you donate to organizations like the Alzheimer's Association that fund independent research. Whether you share this story with someone who might want to participate in research.
Does This Require Action?
If someone in your family has Alzheimer's or you carry known risk factors: this warrants your attention and possibly action. For everyone else: awareness, and perhaps a moment of gratitude for the families who volunteered their pain for science.
Source: NPR
